Role of Rifampin-Based Combination Therapy for Severe Community-Acquired Legionella pneumophila Pneumonia

Abstract

Spanish

French

Objective:

To review the literature concerning the role of rifampin in the combination treatment of Legionella pneumophila pneumonia.

Data Sources:

A search of MEDLINE and Ovid databases was conducted (January 1970-May 2011) using the search terms Legionella pneumophila, pneumonia, Legionnaires' disease, rifampin or rifampicin, macrolide, fluoroquinolone, erythromycin, clarithromycin, levofloxacin, ciprofloxacin, and moxifloxacin

Study Selection and Data Extraction:

In vivo studies published in English that compared antimicrobial therapies including rifampin for the treatment of Legionella pneumonia, as well as in vitro studies including an assessment of rifampin bioactivity, were included.

Data Synthesis:

Macrolides and fluoroquinolones have been effective as monotherapy in the treatment of L. pneumophila pneumonia. This review includes evidence summaries from 4 bioactivity evaluations. 6 clinical studies, and 6 reported cases of combination rifampin use. Combined with supporting evidence, the role of combination rifampin therapy is further delineated.

Conclusions:

Interpretation of the data is limited by the potential for selection bias and lack of consistent comparators. Rifampin therapy should be considered only for patients with severe disease or significant comorbid conditions (eg. uncontrolled diabetes, smoking, or obstructive lung disease) including immunocompromised hosts and those refractory to conventional monotherapy regimens. Caution for significant adverse drug events and drug-drug interactions should be taken with the addition of rifampin.

Keywords

community-acquired pneumonia fluoroquinolone Legionella pneumophila Legionnaires' disease rifampin

Get full access to this article

View all access options for this article.

References

Neil

, Berkelman

. Increasing incidence of legionellosis in the United States, 1990-2005: changing epidemiologic trends. Clin Infect Dis 2008; 47:591–9. DOI 10.1086/590557

Cunha

. Clinical features of legionnaires' disease. Semin Respir Infect 1998; 13:116–27.

World Health Organization. Legionellosis. www.who.int/mediacentre/factsheets/fs285/en/index.html (accessed 2011 Feb 5).

Gupta

, Imperiale

, Sarosi

G A

. Evaluation of the Winthrop-University Hospital criteria to identify Legionella pneumonia. Chest 2001; 120:1064–71. DOI 10.1378/chest.120.4.1064

Ruiz-Gonzalez

, Falguera

, Porcel

. C-Reactive protein for discriminating treatment failure from slow responding pneumonia. Eur J Intern Med 2010; 21:548–52. DOI 10.1016/j.ejim.2010.09.006

Haeuptle

, Zaborsky

, Fiumefreddo

. Prognostic value of procalcitonin in Legionella pneumonia. Eur J Clin Microbiol Infect Dis 2009; 28:55–60. DOI 10.1007/s10096-008-0592-5

Mandell

, Wunderink

, Anzueto

. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44:S27–72. DOI 10.1086/511159

Levy

, Le Jeune

, Woodhead

, Macfarlaned

, Lim

. Primary care summary of the British Thoracic Society Guidelines for the management of community acquired pneumonia in adults: 2009 update. Prim Care Respir J 2010; 19:21–7. DOI 10.4104/pcrj.2010.00014

Woodhead

, Blasi

, Ewig

. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26:1138–80. DOI 10.1183/09031936.05.00055705

10.

South Carolina Department of Health and Environmental Control. 2007-2008 South Carolina annual report on reportable conditions: March 2010. www.scdhec.gov (accessed 2010 Mar 25).

11.

Roig

, Rello

, Yu

. Legionnaires' disease: a guide to diagnosis and therapy. J Respir Dis 2002; 23:229–36.

12.

Salford

, Matsiota-Bernard

, Staikowsky

, Kirstetter

, Frottier

, Nauciel

. Unsuccessful treatment of Legionella pneumophila infection with a fluoroquinolone. Clin Infect Dis 1993; 17:518–9. DOI 10.1093/clinids/17.3.518

13.

Lai

, Tan

, Chou

. Hospital-acquired pneumonia and bacteremia caused by Legionella pneumophila in an immunocompromised patient. Infection 2010; 38:135–7. DOI 10.1007/s15010-009-9253-1

14.

Sopena

, Pedro-Botet

, Mateu

, Tolschinsky

, Rey-Joly

, Sabria

. Community-acquired Legionella pneumonia in elderly patients: characteristics and outcomes. J Am Geriatr Soc 2007; 55:114–9. DOI 10.1111/j.1532-5415.2006.01021.c

15.

Meyer

, Finegold

. Legionnaires' disease. Annu Rev Med 1980; 31:219–32. DOI 10.1146/annurev.me.31.020180.001251

16.

Hays

, Hinthorn

, Chonko

, Liu

. Failure of oral erythromycin therapy for Legionnaires' disease in a renal transplant recipient. South Med J 1981; 74:1422–3.

17.

Rudin

, Evans

, Wing

. Failure of erythromycin in treatment of Legionella micdadei pneumonia. Am J Med 1984; 76:318–20. DOI 10.1016/0002-9343(84)90793-9

18.

Stout

, Arnold

, Yu

. Activity of azithromycin, clarithromycin, roxithromycin, dirithromycin, quinupristin/dalfopristin, and erythromycin against Legionella species by broth microdilution and intracellular susceptibility testing in HL-60 cells. J Antimicrob Chemother 1998; 41:289–91.

19.

Stout

, Arnold

, Yu

. Comparative activity of ciprofloxacin, ofloxacin, levofloxacin, and erythromycin against Legionella species by broth microdilution and intracellular susceptibility testing in HL-60 cells. Diagn Microbiol Infect Dis 1998; 30:37–43. DOI 10.1016/S0732-8893(97)00174-0

20.

Sabria

, Pedro-Botet

, Gomez

. Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. Chest 2005; 128:1401–5. DOI 10.1378/chest.1283.1401

21.

Mykietiuk

, Carratala

, Fernandez-Sabe

. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. Clin Infect Dis 2005; 15:794–9. DOI 10.1086/428059

22.

Haranaga

, Tateyama

, Higa

. Intravenous ciprofloxacin versus erythromycin in the treatment of Legionella pneumonia. Intern Med J 2007; 46:353–7. DOI 102169/internalmedicine.46.6006

23.

Blazquez Garrido

, Espinosa Parra

, Frances

. Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides. Clin Infect Dis 2005; 40:800–6. DOI 10.1086/428049

24.

Jonas

, Engels

, Friedhoff

. Efficacy of moxifloxacin, trovafloxacin, clinafloxacin, and levofloxacin against intracellular Legionella pneumophila. J Antimicrob Chemother 2001; 47:147–52. DOI 10.1093/jac/47.2.147

25.

Ernst

, Gordon

, Hayek

, Silvestri

, Koziel

. Lung abscess complicating Legionella micdadei pneumonia in an adult liver transplant recipient: case report and review. Transplant 1998; 65:130–4.

26.

Nakamura

, Yanagihara

, Izumikawa

. The clinical efficacy of fluoroquinolone and macrolide combination therapy compared with single-agent therapy against community-acquired pneumonia caused by Legionella pneumophila. J Infect 2009; 59:222–4. DOI 10.1016/j.jinf.2009.06.008

27.

Cianciotto

, Edelstein

. Legionella. In: Mandell

, Bennett

, Dolin

, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier, 2010: 2969–84.

28.

Grau

, Antonio

, Ribes

, Salvado

, Garces

, Garau

. Impact of rifampicin addition to clarithromycin in Legionella pneumophila pneumonia. Int J Antimicrob Agents 2006; 28:249–52. DOI 10.1016/j.ijantimicag.2006.03.029

29.

Edelstein

. Chemotherapy of Legionnaires' disease with macrolide or quinolone antimicrobial agents. In: Marre

, Kwaik

, Bartlett

, eds. Legionella. 1st ed. Washington, DC: American Society for Microbiology Press, 2002: 183–8.

30.

Acocella

. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978; 3:108–27. DOI 10.2165/00003088-197803020-00002

31.

Braga

. Antibiotic penetrability into bronchial mucus: pharmacokinetics and clinical considerations. Curr Ther Res 1991; 49:300–27.

32.

Sousa

, Pozniak

, Boffito

. Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs. J Antimicrob Chemother 2008; 62:872–8. DOI 10.1093/jac/dkn33033.

33.

Nielsen

, Bangsborg

, H⊘iby

. Susceptibility of Legionella species to five antibiotics and development of resistance by exposure to erythromycin, ciprofloxacin, and rifampicin. Diagn Microbiol Infect Dis 2000; 36:43–8. DOI 10.1016/S0732-8893(99)00095-4

34.

Kiss

, Farago

, Juhaz

, Bacsa

, Fabian

. Investigation on the serum and lung tissue level of rifampicin in man. Int J Clin Pharmacol Biopharm 1976; 13:42–7.

35.

Van der Auwera

, Matsumoto

, Husson

. Intraphagocytic penetration of antibiotics. J Antimicrob Chemother 1988; 22:185–92. DOI 10.1093/jac/22.2.185

36.

Baltch

, Smith

, Ritz

. Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila. Antimicrob Agents Chemother 1995; 39:1661–6.

37.

Smith

, Baltch

, Franke

, Hioe

, Ritz

, Michelson

. Effect of levofloxacin, erythromycin or rifampicin pretreatment on growth of Legionella pneumophila in human monocytes. J Antimicrob Chemother 1997; 40:673–8. DOI 10.1093/jac/40.5.673

38.

Baltch

, Smith

, Franke

, Michelson

. Antibacterial effects of levofloxacin, erythromycin, and rifampin in a human monocyte system against Legionella pneumophila. Antimicrob Agents Chemother 1998; 42:3153–6.

39.

Horwitz

, Silverstein

. Intracellular multiplication of Legionnaires disease bacteria (Legionella pneumophila) in human monocytes is reversibly inhibited by erythromycin and rifampin. J Clin Invest 1983; 17:15–26. DOI 1172/JCI110744

40.

Product information. Levaquin (levofloxacin). Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc., January 2011.

41.

Product information. Avelox (moxifloxacin). Wayne, NJ: Bayer Healthcare Pharmaceuticals Inc., December 2008.

42.

Product information. Cipro (ciprofloxacin). Wayne, NJ: Bayer Healthcare Pharmaceuticals Inc., March 2009.

43.

Vazifeh

, Bryskier

, Labro

. Mechanism underlying levofloxacin uptake by human polymorphonuclear neutrophils. Antimicrob Agents Chemother 1999; 43:246–52.

44.

Höger

, Vosbeck

, Seger

, Hitzig

. Uptake, intracellular activity, and influence of rifampin on normal function of polymorphonuclear leukocytes. Antimicrob Agents Chemother 1985; 28:667–74.

45.

Bosnar

, Kelneric

, Munic

, Erakovic

, Parnham

. Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and celithromycin. Antimicrob Agents Chemother 2005; 49:2372–7. DOI 10.1128/AAC.49.6.2372-2377.2005

46.

Matera

, Tufano

, Polverino

, Rossi

, Cazzola

. Pulmonary concentrations of dirithromycin and erythromycin during acute exacerbation of mild chronic obstructive pulmonary disease. Eur Respir J 1997; 10:98–103. DOI 10.1183/09031936.97.10010098

47.

Felmingham

, Robbins

, Sanghrajka

, Leakey

, Ridgway

. The in vitro activity of some 14-, 15-, and 16-membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp., and Ureaplasma urealyticum. Drugs Exp Clin Res 1991; 17:91–9.

48.

Cipolli

, Cazzola

, Novelli

. Azithromycin concentrations in serum and bronchial secretions of patients with cystic fibrosis. Clin Drug Invest 2001; 21:353–60. DOI 10.2165/00044011-200121050-0000546

49.

Fish

, Gotfried

, Danziger

, Rodvold

. Penetration of clarithromycin into lung tissues from patients undergoing lung resection. Antimicrob Agents Chemother 1994; 38:876–8.

50.

Anderson

, Joone

, Rensburg

. An in-vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. J Antimicrob Chemother 1988; 22:923–33. DOI 10.1093/jac/22.6.923

51.

Dournon

, Mayaud

, Wolff

. Comparison of the activity of three antibiotic regimens in severe Legionnaires' disease. J Antimicrob Chemother 1990; 26:S129–39. DOI 10.1093/jac/26.suppl_B.129

52.

Howden

, Stuart

, Tallis

, Bailey

, Johnson

. Treatment and outcome of 104 hospitalized patients with legionnaires' disease. Intern Med J 2003; 33:484–8. DOI 10.1046/j.1445-5994.2003.00422.x

53.

Hubbard

, Mathur

, MacFarlane

. Severe community-acquired Legionella pneumonia: treatment, complications and outcome. Q J Med 1993; 86:327–32.

54.

Fine

, Auble

, Yealy

. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243–50. DOI 10.1056/NEJM199701233360402

55.

Hepfer

, Bookstaver

, Rudisill

, Butler

. Combination levofloxacin and rifampin therapy in the treatment of Legionella pneumonia (abstract SP303). Presented at: 43rd ASHP Midyear Clinical Meeting, Orlando, FL, December 7-11, 2008.

56.

Gaillac

, Floccard

, Ould

. Legionella pneumophila pneumonia during pregnancy: a case report. J Infect 2006; 52:e163–4. DOI 10.1016/j.jinf.2005.08.033

57.

Miyara

, Tokashiki

, Shimoji

, Tamaki

, Koide

, Saito

. Rapidly expanding lung abscess caused by Legionella pneumophila in immunocompromised patients: a report of two cases. Intern Med 2002; 41:133–7. DOI 10.2169/internalmedicine.41.133

58.

Tsai

, Lee

, Lin

. Legionnaires' disease in an immunocompetent young adult. Kaohsiung J Med Sci 2001; 17:331–5.

59.

Ito

, Naito

, Kadowaki

. Hot spring bath and Legionella pneumonia: an association confirmed by genomic identification. Intern Med 2002; 41:859–63. DOI 10.2169/internalmedicine.41.859